New Risk • Jul 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (HK$47m sold). Ankündigung • Jun 05
Fangzhou Inc. Showcases Ai-Powered Chronic Disease Management Solution with Tencent Health At Tencent Cloud Conference Fangzhou Inc. attended the 2026 Tencent Cloud AI Industry Applications Summit in Beijing, where it showcased its “AI + Chronic Disease Services” digital solution developed in collaboration with Tencent Health. Fangzhou demonstrated how AI is being integrated into chronic disease management through its “AI + H2H (Hospital-to-Home)” smart healthcare ecosystem. Built on its proprietary XingShi Large Language Model (“XS LLM”), Fangzhou’s AI + Chronic Disease Services solution is designed to enhance care delivery, improve patient outcomes, and expand access to professional healthcare services. Fangzhou’s AI-powered approach focuses on supporting both patients and physicians across the chronic disease management journey. For patients, AI functionality can provide personalized health management recommendations, risk monitoring, and behavioral interventions, helping make long-term care more accessible and effective. For physicians, AI-powered assistants help reduce administrative workloads and streamline routine tasks, enabling doctors to devote more time to diagnosis, treatment, and patient engagement. Fangzhou noted that the integration of AI into chronic disease services is helping to transform healthcare beyond one-time consultations toward continuous, full-cycle health management. By combining advanced technology with long-term patient support, the Company aims to improve service efficiency while strengthening trust and engagement between patients and healthcare providers. The summit also highlighted the ongoing collaboration between Fangzhou and Tencent Health. Since expanding their strategic partnership in November 2025, the two companies have worked together to combine Fangzhou’s healthcare expertise and chronic disease management capabilities with Tencent Health’s technology infrastructure, supporting the development and deployment of AI applications across a broad range of healthcare use cases. Tencent Health’s technology platform provides Fangzhou with access to scalable computing resources and end-to-end model development tools that support the continuous optimization of its AI capabilities. The solution also utilizes Tencent Health’s vector database technology, enabling rapid retrieval from large-scale medical knowledge repositories and improving the accuracy and reliability of AI-generated content. Fangzhou will continue to prioritize technological innovation and ecosystem collaboration as key pillars of its long-term growth strategy. By working closely with Tencent Health and other industry partners, the Company aims to further expand the reach of AI-powered chronic disease services, helping deliver more efficient, personalized, and accessible healthcare support to patients while contributing to the digital transformation of China’s healthcare sector. Ankündigung • May 22
Fangzhou Inc., Annual General Meeting, Jun 16, 2026 Fangzhou Inc., Annual General Meeting, Jun 16, 2026, at 09:30 China Standard Time. Ankündigung • May 14
Fangzhou Inc. Showcases Ai+H2h Chronic Disease Service Innovations Fangzhou Inc. participated in the 2026 National Medical Industry Academic and Industry Integration Conference, held from May 6 to 9 in Wuhan. At the health management sub-forum, Fangzhou presented its innovative “AI+Chronic Disease Service” solutions, addressing some of the most pressing challenges in chronic disease care. In response to persistent challenges facing the healthcare industry, such as physicians’ time constraints, limited patient awareness of chronic disease risks, and poor medication adherence, Fangzhou emphasized the importance of integrated care that connects the hospital and the home. Drawing on a network of 251,000 registered doctors and a robust technology platform, the Company’s AI+H2H (Hospital-to-Home) ecosystem supports a full-cycle approach to chronic disease management. Intelligent tools such as AI Health Assistants and AI Doctor Assistants streamline post-clinic follow-up, improve access to services, and extend care to more patients. Chronic disease management requires long-term engagement. Fangzhou centers its approach on structured follow-ups, evolving from one-off consultations to continuous care over the full course of a patient’s condition. AI-powered tools further improve efficiency. Patient feedback and assessment data are aggregated and reviewed to generate health reports for physicians, significantly reducing the administrative burden without sacrificing quality of care. Long-term members also gain access to tailored health plans, dynamic monitoring, early-warning alerts and individualized medication guidance, ensuring truly comprehensive, ongoing support. In line with trends in intelligent healthcare and collaboration between industry and academia, Fangzhou continues to refine its AI+Chronic Disease Care ecosystem, broadening its service capabilities and enhancing the patient experience. The Company aims to be a trusted long-term health partner, using technology to deliver accessible, high-quality chronic disease management and to set a benchmark for sustainable innovation in healthcare. Reported Earnings • Mar 21
Full year 2025 earnings released: EPS: CN¥0.01 (vs CN¥0.88 loss in FY 2024) Full year 2025 results: EPS: CN¥0.01 (up from CN¥0.88 loss in FY 2024). Revenue: CN¥3.53b (up 30% from FY 2024). Net income: CN¥11.8m (up CN¥866.7m from FY 2024). Profit margin: 0.3% (up from net loss in FY 2024). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Consumer Retailing industry in Hong Kong. Ankündigung • Mar 09
Fangzhou Inc. to Report Fiscal Year 2025 Results on Mar 19, 2026 Fangzhou Inc. announced that they will report fiscal year 2025 results on Mar 19, 2026 Ankündigung • Feb 02
Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Fangzhou Inc. has completed a Follow-on Equity Offering in the amount of HKD 150.00092 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 45,181,000
Price\Range: HKD 3.32
Transaction Features: Subsequent Direct Listing Ankündigung • Jan 27
Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million. Fangzhou Inc. has filed a Follow-on Equity Offering in the amount of HKD 150.00092 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 45,181,000
Price\Range: HKD 3.32
Transaction Features: Subsequent Direct Listing Ankündigung • Jan 26
Fangzhou Inc. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025 Fangzhou Inc. provided preliminary unaudited consolidated earnings guidance for the year ended December 31, 2025. The revenue of the Group is expected to be within the range of approximately RMB 3.50 billion to RMB 3.55 billion for the Reporting Period, representing a growth of approximately 30.0% from revenue of RMB 2,707.4 million for the year ended December 31, 2024. The Group also expects to record net profit of approximately RMB 7 million to RMB 10 million for the Reporting Period, representing a significant increase compared to the net loss before taxation of RMB 854.9 million for the year ended December 31, 2024. The anticipated increase in revenue was primarily due to continued growth across the Company's consumer facing business segments as attracted more patients and doctors to platform. The turnaround to profit was mainly attributable to increased revenue, and a reduction in equity-settled share-based transactions. Ankündigung • Nov 27
Fangzhou Inc. and Tencent Healthcare Launch Full-Stack AI Solution for Chronic-Disease Management Fangzhou Inc. and Tencent Healthcare jointly launched a comprehensive "AI+Chronic Disease Management" solution, marking a major step in the wider deployment of artificial intelligence across China's healthcare sector. The partnership provides industry partners with an integrated technology pipeline, from model training and scenario verification to deployment, aimed at advancing chronic-disease management into a new phase of intelligent, and high-efficiency service delivery. The solution is built on Fangzhou's AI+H2H (H Hospital to Home) ecosystem, a core architecture that embeds proprietary large-model capabilities into chronic-disease workflows. Tencent Cloud, as a leading cloud services provider, offers extensive capabilities in core technological domains including cloud computing, big data, and artificial intelligence. This strategic collaboration will provide a robust technological foundation for the transformation of AI-enhanced chronic disease management. This launch follows Fangzhou's recent AI growth momentum. The October introduction of the Company's "medical report interpretation" feature saw particularly strong adoption, addressing a widespread patient need to better understand complex lab results. Rising engagement levels and session frequency also reflect growing user confidence in AI capabilities. Safety and compliance remain central to Fangzhou's approach. To address the risk of AI hallucinations in sensitive clinical settings, the company has implemented multiple layers of protection, including reinforcement learning with curated knowledge bases, rule-based supervision, and medical-scenario alignment checks. Fangzhou has built its model on Tencent Healthcare's TI platform, leveraging one-stop training, evaluation and deployment pipelines to enable continuous model optimization. Tencent Healthcare's vector database, capable of storing hundreds of billions of domain-specific medical knowledge entries, provides millisecond-level semantic evaluation and improves the accuracy and factuality of RAG-based outputs. For compliance assurance, Tencent Healthcare's AI security WAF supplies fine-grained threat detection and encrypted safeguarding of sensitive medical data, ensuring the solution aligns with regulatory standards for clinical AI. The partnership aligns closely with the National Health Commission's recently issued guidelines on developing safe, standardized "AI + healthcare" applications. Both companies indicated their joint solution will help accelerate digital transformation in chronic care, strengthen medical-service delivery, and support long-term national health goals under the "Healthy China 2030" initiative. Ankündigung • Oct 22
Fangzhou Inc. Announces Leveraging Its Proprietary “Xingshi” Large Language Model Fangzhou Inc. announced leveraging its proprietary “XingShi” Large Language Model (“XS LLM”), the company's system integrates AI-enabled tools such as its AI Doctor Assistant, AI Health Manager, and AI Medication Finder to deliver a closed-loop weight management solution. Users can upload their BMI data or health reports to receive tailored recommendations, while patients requiring medication can access 24/7 AI-assisted guidance and follow-up support from licensed medical professionals. Earlier this year, Fangzhou announced strategic partnerships with Novo Nordisk and Innovent Biologics to build AI-powered weight management solutions, representing a significant advance in digital healthcare collaboration. At the symposium, Fangzhou was named as a founding core enterprise of the national “Healthy China: AI + Weight Management Pioneer” initiative, a collaborative effort focused on setting industry standards, fostering innovation, and educating the public on evidence-based weight management. Looking ahead, Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration. By building a smart, standardized, and collaborative framework, the Company aims to transform China’s weight management landscape and contribute to long-term national health priorities. Recent Insider Transactions • Oct 05
Executive Director recently sold HK$21m worth of stock On the 30th of September, Yuming Zou sold around 5m shares on-market at roughly HK$4.27 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Yuming's only on-market trade for the last 12 months. Reported Earnings • Sep 28
First half 2025 earnings released: EPS: CN¥0.009 (vs CN¥1.27 loss in 1H 2024) First half 2025 results: EPS: CN¥0.009 (up from CN¥1.27 loss in 1H 2024). Revenue: CN¥1.49b (up 13% from 1H 2024). Net income: CN¥12.5m (up CN¥831.2m from 1H 2024). Profit margin: 0.8% (up from net loss in 1H 2024). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in Hong Kong. Ankündigung • Sep 15
Fangzhou Unveils "XingShi" Large Language Model to Advance AI-Driven Chronic Disease Management Fangzhou Inc. announced the release of its proprietary "XingShi" Large Language Model ("XS LLM"), an AI system engineered to address critical inefficiencies in chronic disease management by improving service efficiency, delivering improved personalization, and helping to make better use of physicians' available time. XS LLM integrates multimodal capabilities -- image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning -- while achieving advanced performance benchmarks in medical AI. This core system supports five domain-specific intelligent agents: "AI Knowledge Agent", "AI Guidance Agent", "AI Pre-Consult Agent", "AI Doctor Assistant", and "AI-Electronic Medical Record (EMR) Agent". Together, these agents create a closed-loop service architecture spanning the full lifecycle of chronic disease management. Built as the "core digital brain" of Fangzhou's platform, the model currently powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product addresses distinct clinical and patient-side use cases, enabling real-time, precision interventions across medication guidance, patient education, diagnostic assistance, and medical reference. This launch reflects Fangzhou's steady AI build-out: from the introduction of its H2H (Hospital-to-Home) digital ecosystem, to the deployment of AI-powered customer service and knowledge base systems, and now to an enterprise-grade medical LLM. With China's "AI+" policy framework accelerating industrial adoption, Fangzhou indicated that XS LLM will anchor future R&D in chronic disease management applications, reinforcing its mission of delivering scalable, precision healthcare. Reported Earnings • Aug 29
First half 2025 earnings released: EPS: CN¥0.009 (vs CN¥1.27 loss in 1H 2024) First half 2025 results: EPS: CN¥0.009 (up from CN¥1.27 loss in 1H 2024). Revenue: CN¥1.49b (up 13% from 1H 2024). Net income: CN¥12.5m (up CN¥831.2m from 1H 2024). Profit margin: 0.8% (up from net loss in 1H 2024). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in Hong Kong. New Risk • Aug 28
New major risk - Revenue and earnings growth Earnings have declined by 11% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Significant insider selling over the past 3 months (HK$63m sold). Ankündigung • Aug 15
Fangzhou Inc. to Report First Half, 2025 Results on Aug 27, 2025 Fangzhou Inc. announced that they will report first half, 2025 results on Aug 27, 2025 Ankündigung • Jun 20
Fangzhou Inc. Appoints KANG Wei as Member of Nomination Committee, Effective from June 18, 2025 The board of directors of Fangzhou Inc. announced that, Ms. KANG Wei, an independent non-executive Director, has been appointed as a member of the nomination committee of the Company, effective from June 18, 2025. Following this appointment, the Nomination Committee now comprises four members, namely Mr. XIE Fangmin (chairman), Dr. WANG Haizhong, Ms. KANG Wei and Mr. ZHU Xiaolu. Ankündigung • May 28
Fangzhou Inc., Annual General Meeting, Jun 19, 2025 Fangzhou Inc., Annual General Meeting, Jun 19, 2025, at 09:15 China Standard Time. Reported Earnings • Apr 24
Full year 2024 earnings released: CN¥0.88 loss per share (vs CN¥0.35 loss in FY 2023) Full year 2024 results: CN¥0.88 loss per share (further deteriorated from CN¥0.35 loss in FY 2023). Revenue: CN¥2.71b (up 11% from FY 2023). Net loss: CN¥854.9m (loss widened 334% from FY 2023). Ankündigung • Apr 14
Fangzhou Presents Ai-Driven Healthcare Ecosystem At Guangzhou Biotech Innovation Salon Fangzhou Inc. participated in the "AI Empowers Biopharma" exchange panel hosted by the Guangzhou Development District Talent Education Group on April 3, 2025, joining 28 enterprises to explore cutting-edge applications of AI healthcare. Mitigate AI hallucinations: The Company also unveiled its proprietary framework to mitigate AI hallucinations in medical applications, combining a self-developed training platform with a professional medical knowledge base and data sandbox. This approach powers Fangzhou's "AI Agent Matrix," featuring round-the-clock diagnostic support, intelligent customer service tools, and AI-assisted health content creation, collectively enhancing care accessibility while reducing operational costs. Blueprint for Vertical AI Leadership: Moving forward, Fangzhou will intensify its focus on the vertical field of AI + Healthcare, leveraging its proven H2H Smart Healthcare Ecosystem to drive deeper integration of AI across online healthcare use cases. The Company will seize opportunities like this panel to strengthen collaboration with biopharmaceutical enterprises and research institutions, fostering synergistic development between regional biomedicine and smart healthcare. AI-Powered Growth Strategy: Fangzhou's growth strategy centers on deploying cutting-edge AI technologies like DeepSeek-V3 while deepening partnerships with industry leaders such as Tencent Health and Tencent Cloud. These initiatives are designed to push the boundaries of AI-powered healthcare, strengthen the Company's technological leadership, and fast-track the market adoption of its innovations — all with the goal of delivering superior care experiences and enhanced solutions for patients and users. Reported Earnings • Mar 22
Full year 2024 earnings released Full year 2024 results: Revenue: CN¥2.71b (up 11% from FY 2023). Net loss: CN¥854.9m (loss widened 334% from FY 2023). Ankündigung • Mar 12
Fangzhou Inc. to Report Fiscal Year 2024 Results on Mar 21, 2025 Fangzhou Inc. announced that they will report fiscal year 2024 results on Mar 21, 2025 Ankündigung • Feb 18
Fangzhou Inc. Integrates DeepSeek Open-Source Ai Model to Enhance Internet Healthcare Fangzhou Inc. announced the successful integration and local deployment of the DeepSeek-R1 open-source large language model on February 8th. This upgrade is expected to yield improvements in the company's service capabilities and operational efficiency, enabling more precise and personalized healthcare solutions for patients and healthcare providers, contributing to the overall advancement of the Internet healthcare sector. The local deployment of DeepSeek-R1's advanced analytical and reasoning capabilities allows Fangzhou to deliver data-driven decision support and advanced functionality, while maintaining full control over privacy and data security. By leveraging DeepSeek's technical strengths, the platform can more effectively address the needs of a diverse user base of patients and healthcare providers. For Patients: The platform enhances health management by providing analysis of medical reports, test results, and other health data. Leveraging these insights, healthcare providers are able to offer medication guidance, and post-diagnosis care plans. For Healthcare Providers: Fangzhou's DeepSeek-R1 powered "AI Assistant" can streamline prescription reviews and patient management, allowing doctors to focus on more critical medical tasks. The model's data-driven logic also incorporates science-based decision support, aiding in diagnosis and optimized treatment plans. Buy Or Sell Opportunity • Feb 07
Now 23% overvalued Over the last 90 days, the stock has fallen 56% to HK$3.31. The fair value is estimated to be HK$2.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only. New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-CN¥2.0b). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). Ankündigung • Dec 02
Fangzhou Inc. Launches AI Agent Solution Fangzhou Inc. unveiled its healthcare-focused "AI Agent Solution", a suite of tools designed to facilitate access to healthcare information and analysis for both consumers and healthcare professionals. Consumers can utilize Fangzhou's mini program to easily find health and diagnosis information, along with easy-to-understand "personalized interpretation" of over fifty types of medical reports. For healthcare providers, Fangzhou's "AI Academic Interaction Assistant" enhances the efficiency of scientific content research, with support for voice input, and Chinese/English bilingual search output, and automated literature summaries, significantly reducing search time by up to 80%. This commitment to technological innovation not only creates new pathways for health management but also supports Fangzhou's mission of empowering users and healthcare professionals alike with cutting-edge solutions. Reported Earnings • Aug 31
First half 2024 earnings released First half 2024 results: CN¥1.27 loss per share. Net loss: CN¥818.7m (flat on 1H 2023). Ankündigung • Aug 29
Fangzhou Inc. Announces Change of Joint Company Secretary The board of directors of Fangzhou Inc. announced that Ms. Fung Po Ting ("Ms. Fung") has tendered her resignation as the joint company secretary of the Company (the "Joint Company Secretary") and the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent") due to other work arrangements, with effect from August 28, 2024. Ms. Fung has confirmed that there is no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "Stock Exchange") in relation to her resignation. The Board is also pleased to announce that Ms. Ng Sau Mei ("Ms. Ng") has been appointed by the Company as the Joint Company Secretary and the Process Agent in replacement of Ms. Fung, with effect from August 28, 2024. Mr. Zou Yuming ("Mr. Zou") will continue to serve as the other Joint Company Secretary. Mr. ZOU Yuming, aged 43, is executive Director and chief financial officer. He has been Director since August 9, 2021 and was re-designated as an executive Director in September 2021. He is responsible for corporate finance and financial management of the Group, investor relations, and secretarial affairs of the Board. Mr. Zou joined Group as vice president of strategic development in August 2018 and was appointed as chief financial officer in April 2021. Prior to joining Group, Mr. Zou served as a trader and an executive director in JP Morgan Chase & Co. from July 2003 to July 2018. Since January 2020, he has served as an independent non-executive director of eCargo Holdings Limited, a company listed on the Australian Securities Exchange. Mr. Zou received both a bachelor's degree in economics and a master's degree in statistics from Harvard University in Cambridge, Massachusetts, the US in June 2003. Mr. Zou is a Chartered Financial Analyst (CFA) and obtained the qualification from the Chartered Financial Analyst Institute in 2009. Ms. Ng is the director and head of the Listing Services Department of TMF Hong Kong Limited and is responsible for provision of corporate secretarial and compliance services to listed company clients. She has over 20 years of experience in the company secretarial field and has extensive knowledge and experience in dealing with corporate governance, regulatory and compliance affairs of listed companies. Ms. Ng holds a Master's Degree in Laws from University of London in the United Kingdom and a Bachelor's Degree in Laws from City University of Hong Kong, and is a Chartered Secretary, a Chartered Governance Professional and a fellow member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Ankündigung • Aug 17
Fangzhou Inc. to Report Q2, 2024 Results on Aug 28, 2024 Fangzhou Inc. announced that they will report Q2, 2024 results on Aug 28, 2024 Ankündigung • Jul 09
Fangzhou Inc. has completed an IPO in the amount of HKD 194.684 million. Fangzhou Inc. has completed an IPO in the amount of HKD 194.684 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,140,000
Price\Range: HKD 8.18
Discount Per Security: HKD 0.6544
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 16,660,000
Price\Range: HKD 8.18
Discount Per Security: HKD 0.6544
Transaction Features: Regulation S; Rule 144A 
